Cartherics wins second Japanese patent for cell therapy platform

Cartherics said June 10, 2026, that the Japanese Patent Office has granted a patent covering genetically modified stem cells and their uses, adding to the company’s IP position for its CAR-engineered cell therapy pipeline. The Melbourne biotech says the filing supports commercialization plans for its lead ovarian cancer program and could also extend to endometriosis applications.

Why it matters: - The Japanese grant expands Cartherics’ patent coverage in a market that is important for regenerative medicine and advanced cell therapies. - The patent strengthens the company’s position around CAR-engineered immune cell products as it moves toward clinical development and future partnering. - Japan is especially relevant for Cartherics because endometriosis-associated ovarian cancer is more prevalent there than in Western countries.

What happened: - Cartherics announced on June 10, 2026, that the Japanese Patent Office issued a patent for “Genetically modified cells and uses thereof.” - The patent is the second granted in Japan under this patent family. - Cartherics is a Melbourne-based biotechnology company developing off-the-shelf immune cell therapies for women’s diseases, with lead programs in ovarian cancer and endometriosis.

The details: - The patent covers stem cells, including induced pluripotent stem cells (iPSCs), that have been gene edited to include Cartherics’ chimeric antigen receptor, or CAR, constructs. - The coverage applies to cancer uses and potentially to endometriosis. - Cartherics said the grant extends its proprietary position across its cell therapy pipeline. - CEO Ian Nisbet said the company has invested heavily in an iPSC-derived CAR-iNK cell platform covered by an extensive patent portfolio. - Cartherics’ lead product is CTH-401, a CAR-iNK cell product targeting the tumor antigen TAG-72. - The company has started manufacturing clinical trial material in upgraded clean rooms. - Cartherics plans to file an Investigational New Drug application in late 2026. - The company expects to begin its first human ovarian cancer trial shortly after the IND filing. - In Japan, clear cell carcinoma accounts for about 25% of epithelial ovarian cancers, compared with 5% to 10% in Western countries. - Clear cell and endometrioid ovarian cancers often arise from preexisting endometriosis.

Between the lines: - The Japanese patent adds protection around a platform Cartherics wants to use across multiple cancer and non-cancer indications, not just one drug candidate. - The company is signaling that its IP strategy is part of the commercial case for entering larger partnering and development discussions. - The Japan-specific disease data helps explain why Cartherics is emphasizing the market, even before any clinical data from CTH-401.

What’s next: - Cartherics will keep building its global patent estate around CAR-engineered cell therapies. - The company plans to submit its IND in late 2026. - Cartherics expects to start its first human trial in ovarian cancer soon after the IND filing. - Further development may also support endometriosis-focused cell therapy programs.

The bottom line: - Cartherics has added another layer of patent protection in Japan just as it prepares to move its lead CAR-iNK program toward the clinic.